Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

University of British Columbia

$17,500.00

Identifying Modifiers of EGFR Induced Tumorigenesis to Develop New Therapeutic Strategies for Lung Cancer

FY 2022-23

Summary
Lung cancer is the most common type of cancer and is responsible for nearly a quarter of all cancer deaths in Canada. Targeted therapies are drugs that specifically work to shut down mutated genes that cancer cells rely on to multiply and survive. For example, one of the most common genes that drives lung cancer is called Epidermal Growth Factor Receptor (EGFR), and this gene is targeted through drugs called Tyrosine Kinase Inhibitors (TKIs). Patients that have tumors with mutant EGFR demonstrate a dramatic initial response to TKIs, but while these treatments have greatly improved outcomes for many lung cancer patients, almost all people develop resistance to these drugs over time.One strategy to increase TKI response time is to combine targeted therapy with other treatments that inhibit genes that drive resistance. Previous work in our lab identified a set of candidate genes mutated in EGFR driven lung cancers in both mouse models and human patients, many of which have not been previously implicated in lung cancer development. My project aims to determine which of these genes are involved in driving essential processes in EGFR mutant lung cancers - including TKI drug resistance - using a targeted gene disruption screen. This work will greatly increase our knowledge of lung cancer progression and lay the groundwork for future lung cancer therapies that can be combined with targeted agents to improve patient survival.
Program
Master's Award: Canada Graduate Scholarships
Location
British Columbia, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
486395
Name
Jajarmi Jana
Region
British Columbia
Country
Canada
Orgtype
Institution Paid; Research Institution
Prcname2
Special Cases - Awards Programs
Projecttitle
Identifying Modifiers of EGFR Induced Tumorigenesis to Develop New Therapeutic Strategies for Lung Cancer
Programtype2
Studentship Programs
Orgnameinp2
University of British Columbia
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Cooperative Drivers; Crispr; Egfr; Genetics; Non-Small Cell Lung Cancer
Abstract
Lung cancer is the most common type of cancer and is responsible for nearly a quarter of all cancer deaths in Canada. Targeted therapies are drugs that specifically work to shut down mutated genes that cancer cells rely on to multiply and survive. For example, one of the most common genes that drives lung cancer is called Epidermal Growth Factor Receptor (EGFR), and this gene is targeted through drugs called Tyrosine Kinase Inhibitors (TKIs). Patients that have tumors with mutant EGFR demonstrate a dramatic initial response to TKIs, but while these treatments have greatly improved outcomes for many lung cancer patients, almost all people develop resistance to these drugs over time.One strategy to increase TKI response time is to combine targeted therapy with other treatments that inhibit genes that drive resistance. Previous work in our lab identified a set of candidate genes mutated in EGFR driven lung cancers in both mouse models and human patients, many of which have not been previously implicated in lung cancer development. My project aims to determine which of these genes are involved in driving essential processes in EGFR mutant lung cancers - including TKI drug resistance - using a targeted gene disruption screen. This work will greatly increase our knowledge of lung cancer progression and lay the groundwork for future lung cancer therapies that can be combined with targeted agents to improve patient survival.
Competitiondate
202212
Approvedterm2
1 yr 0 mth
Pinamesdelim
Jajarmi, Jana
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~